iNtODEWORLD | AMR Industry Alliance Progress Report Published – SAL200 as “Notable Technologies in Development”
17261
single,single-post,postid-17261,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

AMR Industry Alliance Progress Report Published – SAL200 as “Notable Technologies in Development”

Geneva, 18 January 2018 – The AMR Industry Alliance launches its first report that shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (AMR). The Alliance brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries.

Today, an estimated 700,000 people die each year because of the growing number of potentially deadly infectious pathogens. These include pathogens that cause tuberculosis, HIV, malaria, and staph infections, which have developed resistance to treatment regimens. AMR has the potential to turn back the clock on modern medicine. In response to this public health threat and its social and economic consequences, the United Nations in 2016 called for concerted action from governments and various sectors to address the implications of AMR. The AMR Industry Alliance is the life sciences industry’s response to this call for action.

Necessity of First-in-class Drug

According to the report, around 700,000 people die each year because of the deadly infectious pathogens, including those that cause tuberculosis, HIV, malaria and staph infections, that have developed resistance to treatment regimens. AMR is considered to be one of the most severe crisis for humanity since it has the potential to turn the clock back on modern medicine which may cause catastrophic disaster. The United Nations called in 2016 for concerted action from governments and various sectors, to address the implications of antimicrobial resistance. The AMR Industry Alliance is the life sciences industry’s response to call for action.

First-in-class SAL200

AMR categorizes iNtRON Bio’s SAL200 as a notable first-in-class drug and displays the profile of the program on their website (https://www.amrindustryalliance.org/case-study/n-rephasin-sal200-tonabacase/). Conventional antibiotics are designed to interrupt bacterial synthesis or metabolism, but finally bacteria find a way to survive under such inhibitors, and that is what we call antimicrobial resistance. On the other hand, SAL200 utilizes totally different mechanism from the conventional antibiotics since it does not interrupt but destroy peptidoglycan structure of the target bacteria, so that the bacteria is completely lysed with no time to develop resistance to SAL200. SAL200’s MoA is very specifically destroy target bacteria, and regardless of AMR existence, it acts rapidly but safely yet.

iNtRON Bio is utilizing world-class endolysin R&D platform to accelerate new drug development for life threatening gram positive and negative bacteria infection.

it is iNtRON.



iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.